Wednesday, February 10, 2016 6:38:20 PM
As I understand it that is only true if Fast Track was applied for and approved. I would have expected that to have been reported if it happened and I would have expected it to happen by now if it was going to happen at all.
It was applied for and approved for B-OM...here's why:
FDA on Fast Track criteria:
"Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
Any drug being developed to treat or prevent a condition with no current therapy obviously is directed at an unmet need."
CTIX PR:
"There are no FDA approved drugs for the prevention of oral mucositis."
I suspect that Fast Track was either not applied for or not granted for B-ABSSSI because it was felt that it didn't meet the above criteria.
That leaves an open question as to what this really means:
"The company is also eligible for Fast Track and Priority Review under QIDP."
This is the quote from the company release of 12/8/14.....I have also seen very similar language in other literature.
"Receiving QIDP designation means that Brilacidin is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity. - See more at: http://cellceutix.com/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda/#sthash.XzrG2Xym.dpuf
It's not clear to me how the QIDP designation makes the drug eligible for Fast Track, however. Maybe someone else can document the connection, assuming there is one.
It's morally wrong to allow a sucker to keep his money.......Cuthbert J. Twillie
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM